Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588276 | 0.82 | HDAC1 (0.41) | HDAC1HDAC3HDAC2HDAC4ALDH1A1 | |
| SCHEMBL25801563 | 0.81 | HDAC1 (0.37) | HDAC1HSD11B1HDAC3HDAC2HDAC6 | |
| SCHEMBL25802892 | 0.81 | HDAC4 (0.35) | HDAC1SLC6A3HDAC4SLC6A4 | |
| SCHEMBL23588091 | 0.81 | HDAC4 (0.35) | HDAC1HDAC4OPRM1 | |
| SCHEMBL18603143 | 0.81 | HDAC4 (0.54) | HDAC1HSD11B1HDAC3HDAC2HDAC6 | |
| SCHEMBL23588199 | 0.80 | THRB (0.47) | HDAC1HDAC3HDAC2HDAC6APP | |
| SCHEMBL23588194 | 0.80 | KDM1A (0.40) | HDAC4 | |
| SCHEMBL838360 | 0.80 | HDAC4 (0.52) | HDAC1HSD11B1HDAC4 | |
| SCHEMBL20116463 | 0.77 | ALDH1A1 (0.46) | HDAC1HDAC3HDAC2HDAC6CYP3A4 | |
| SCHEMBL23578076 | 0.76 | SLC6A4 (0.46) | CYP3A4SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2008050200-A1 | OXADIAZOLE COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | HDAC1 2153/4885HSD11B1 528/4885HDAC3 2470/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | HDAC1 2136/4885HSD11B1 648/4885HDAC3 2488/4885 |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | HDAC1 1829/4885HSD11B1 1964/4885HDAC3 947/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | HDAC1 2153/4885HSD11B1 528/4885HDAC3 2470/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HDAC1 1862/4885HSD11B1 741/4885HDAC3 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.